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Abstract
Obsessive compulsive disorder (OCD) is a psychiatric disorder characterized by
recurrent intrusive thoughts (obsessions) that cause significant anxiety and distress, leading to
repetitive behaviors (compulsions) that an individual feels driven to perform. The symptoms
of OCD can range from mild to so severe that it can be incapacitating to an individual’s life.
Treatment is often prescribed, including both pharmacological and behavioral therapy.
Overall, 70% of patients starting treatment experience a significant improvement; however,
there is still a portion of patients with severe OCD that do not respond to first and second-line
treatment plans. We present the case of a 62-year-old-male who was admitted to inpatient
psychiatry for severe OCD. The patient failed to respond to first- and second-line treatment
options and was prescribed ondansetron for his obsessive thoughts. Ondansetron is a 5-HT3
receptor antagonist indicated for the treatment and prevention of nausea and vomiting. Our
patient successfully responded to an off-label use of ondansetron for obsessive thoughts in
OCD.

Introduction
Obsessive-Compulsive Disorder (OCD) is a relatively common psychiatric disorder
that causes significant distress and impairment in function. OCD is characterized by recurrent
intrusive thoughts that typically causes significant anxiety and distress that leads to repetitive
behavioral acts. The treatment for OCD includes both behavioral therapy and
pharmacological treatment options. Most patients respond to the standard treatment options;
when first- and second-line treatment options fail, the chronicity and severity of the disease
can be debilitating to a patient’s life. Presented is a case in which first- and second-line
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treatment options failed when prescribed. Ondansetron (Zofran), a 5HT3 antagonist, is a
common medication used for the treatment and prevention of nausea and vomiting. This
medication was prescribed to our patient as an off-label attempt to treat obsessive thoughts.
The treatment options for OCD, including the use of ondansetron and other 5-HT3 antagonists
as alternative or augmentative treatment options, will be discussed.

Case Synopsis
A 62-year-old male was admitted to inpatient psychiatry with suicidal ideations due to
severe anxiety. The patient had a significant past medical history of OCD, diagnosed at 22
years of age. He complained of severe anxiety rated 10/10 and suicidal ideations without a
plan. During the hospital stay, the patient reported that 10 hours per day, he thought about
washing his hands to avoid contamination because of his obsession with cleanliness. He
refused to shake hands or touch door knobs without compulsively washing his hands
afterwards. He reported that these obsessions and compulsions made it impossible for him to
have any enjoyment in life. The patient appeared to be very anxious upon physical
examination, with noticeable hand tremors and an erythematous dry flaky rash noted on his
hands due to excessive washing.
The patient was taking a tricyclic antidepressant, clomipramine, 50 mg orally at night
for his obsessive thoughts; a serotonin reuptake inhibitor, fluoxetine, 40 mg orally daily and a
benzodiazepine, clonazepam, 2 mg orally daily for his anxiety for years prior to admission.
This treatment plan was only providing minimal improvement in his symptoms. It was
decided to add an anxiolytic, buspirone, 10 mg by mouth twice daily, to help control his
anxiety, which was only minimally effective. Due to the development of severe hypotension
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from the clomipramine, the medication was switched to an atypical antipsychotic, lurasidone,
40 mg by mouth daily for his obsessive thoughts. Hypotension again developed, and the
medication was discontinued. At this point, the patient was started on an antiemetic,
ondansetron, 0.25 mg twice daily orally, as an off-label attempt to treat the patient’s obsessive
thoughts. After two weeks of being on this medication, the patient responded well to the
ondansetron, reporting a better mood, fewer compulsions to wash his hands, and a decrease in
anxiety which he rated 6/10. He denied any suicidal ideations, intent or plan.
The patient was no longer an imminent threat to himself or others and was discharged
from the hospital with prescriptions for ondansetron 0.5mg by mouth twice daily, fluoxetine
40mg by mouth once daily, and clonazepam 1mg by mouth twice daily, as needed for anxiety.

Literature Review
Obsessive compulsive disorder (OCD) is a psychiatric disorder characterized by
recurrent intrusive thoughts (obsessions) that cause significant anxiety and distress that leads
to repetitive behaviors (compulsions) that individuals feel driven to perform to relieve that
anxiety. OCD typically starts in childhood, persists throughout a lifetime, and can cause
significant impairment in function due to the severity and chronicity of the disorder.1
Treatment options include both pharmacologic and behavioral therapies. Most patients
starting treatment for OCD respond well, however about 30% of patients fail first and secondline treatment options. These patients with moderate to severe OCD who fail standard
treatment options may be significantly debilitated due to the chronicity and severity of the
disease.
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Selective serotonin reuptake inhibitors (SSRIs) are the first line of treatment for
OCD.1 Tricyclic antidepressants and atypical antipsychotics are the second line of treatment
in patients where SSRIs are ineffective; however, ondansetron holds promise as a new
alternative when first- and second-line treatment options fail. OCD is linked to decreased
levels of serotonin and increased levels of dopamine in the brain, which implies two possible
mechanisms for how ondansetron may be beneficial in the treatment of OCD. Ondansetron
blocks the 5-HT3 receptor, which, in combination with the blockade of serotonin reuptake,
allows for higher-than-normal serotonin levels in the brain. In addition, 5-HT3 blockage may
have a weak, downstream inhibitory effect on dopaminergic neurotransmission; as 5-HT3
receptors act indirectly by inhibiting cortico-mesolimbic dopamine release, thus decreasing
dopamine levels.2,3 In addition, inhibition of the 5-HT3 receptor with a genetic variant related
to the “washing” phenotype expressed with OCD could limit activity of the ion channel
controlled by the 5-HT3 receptor.2
Although numerous studies have shown inconclusive results, several studies show that
5-HT3 antagonists are efficacious and are proven to be safe in patients with OCD.4,5,6 In the
work of Heidari et al, the 5-HT3 antagonist, ondansetron, was shown to be beneficial when
used as an augmentative agent to fluvoxamine, an SSRI, in the treatment of patients with
moderate to severe OCD with no significant adverse events reported.7 Neda et al showed
similar results augmenting fluvoxamine, an SSRI, with granisetron, a 5-HT3 receptor
antagonist. Patients in the study responded successfully to granisetron as an adjunct to
fluvoxamine.4 Even though the results from the mentioned studies are inconclusive, they
display promise for the use of ondansetron in the treatment of OCD without significant
adverse effects. Thus, ondansetron may be beneficial as an alternative treatment option in
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patients with moderate to severe OCD who have failed to respond first and/or second line
treatment options.2,4,5

Discussion
Obsessive compulsive disorder can be incapacitating to an individual’s life if left
untreated or symptoms are unresponsive to standard treatment options. Typically, about 70%
of patients starting pharmacologic treatment respond positively and can continue their lives
without any impairment. However, some patients do not respond to first and second-line
treatment options, which can cause significant impairment in daily function. Our patient failed
all traditional options for the treatment of OCD. When admitted to the inpatient psychiatric
unit, the patient was on an SSRI, fluoxetine, which is first line for the treatment of OCD. He
was also on clomipramine, a tricyclic antidepressant, which is a second line treatment option
for patients with OCD. Unfortunately, the patient did not respond to the medications he was
originally prescribed. Other second line treatment options such buspirone and lurasidone were
prescribed in attempt to treat his symptoms, however, the attempts were unsuccessful. Our
patient failed to respond to first and second line treatment options, leaving his symptoms
uncontrolled. It is important to recognize that the patient’s quality of life may be affected due
to the severity and treatment failures in OCD. These patients may benefit from other treatment
options such as ondansetron and other 5-HT3 antagonists as alternative treatment options.
According to recent literature, ondansetron, and other 5HT3 antagonists, may be
beneficial in the treatment of obsessive compulsive disorder and is proving to be safe in these
patients.2,3,4 Heidari, Zarei , Hosseini et al, displayed evidence that ondansetron was shown to
provide a beneficial effect when used in conjunction with fluvoxamine in the treatment of
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patients with moderate to severe OCD, without any adverse effects.7 Likewise, our patient
was prescribed fluoxetine, an SSRI similar to fluvoxamine, and showed significant
improvement in OCD symptoms with the addition of ondansetron. Neda, Mahdieh,
Mohammad et al showed similar results augmenting fluvoxamine with granisetron, another 5HT3 receptor antagonist similar to ondansetron.4 Patients in the study responded successfully
to granisetron as an adjunct to fluvoxamine, comparable to how our patient responded to
ondansetron as an adjunctive treatment to a similar SSRI.
When trying to understand the role of ondansetron in the treatment of obsessive
thoughts, it is important to recognize the pathophysiology of OCD. OCD is linked to
decreased levels of serotonin and increased levels of dopamine, two common
neurotransmitters found in the brain.3 This implies that there may be two possible
mechanisms for how ondansetron may be beneficial in the treatment of OCD. Ondansetron
blocks the 5-HT3 receptor, which, in combination with the blockade of serotonin reuptake via
inhibition by the SSRIs, allows for an increase in the serotonin levels in the brain. The
addition of ondansetron allows for greater increase in serotonin levels, than would an SSRI
alone. This provides evidence that when ondansetron is added in combination with a selective
serotonin reuptake inhibitor, better treatment of obsessive thoughts may be achieved.3 This
parallels the treatment regimen our patient was trialed on. He was taking fluoxetine, and, with
the addition of ondansetron, he showed significant improvement in his symptoms.
Another proposed mechanism explaining the use of ondansetron in the treatment of
OCD is through the inhibition and thus downfield effects of dopamine. Through 5-HT3
blockage, ondansetron has a weak, downstream inhibitory effect on dopaminergic
neurotransmission; 5-HT3 receptors act indirectly by inhibiting cortico-mesolimbic dopamine
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release, thus decreasing dopamine levels in the brain.3 A further possibility is the inhibition of
the 5-HT3 receptor with a noted genetic variant linked to OCD. In a study published by
Lennertz and colleagues, the HTR3E genetic variant p.T86A was found to have a significant
association with the “washing” obsession found primarily in males. The phenotypic
expression of this genetic variant was not directly discussed, but administration of 5-HT3
antagonists like ondansetron were found to diminish the “washing” action of OCD patients
expressing this HTR3E variant. More evidence would be needed for our specific patient to
identify this genetic variant possibly being present.2
Although numerous studies have shown inconclusive results, several studies show
that 5-HT3 antagonists are efficacious and are proven to be safe in patients with OCD.4,5,6 Our
patient provides an example of the severity obsessive compulsive disorder can progress to if
left untreated or is unresponsive to standard treatment options. This case supports the current
literature on the use of ondansetron, and other 5-HT3 receptor antagonists, in the treatment of
obsessive thoughts. Our patient successfully responded to this off-label attempt to treat OCD.
The patient was discharged home to his family on a low dose of ondansetron in addition to
fluoxetine and clonazepam. Although more research needs to be done for ondansetron to
formally receive this indication, 5 -HT3 receptor antagonist are showing promise as an
alternative treatment option in the patients with moderate to severe OCD, refractory to current
standard medication treatment options.
Conclusion
Obsessive-compulsive disorder is a very common psychiatric condition. Most patients
respond to pharmacological treatment options, however, when first- and second-line treatment
options fail, the chronicity and severity of the disease can be debilitating to a patient’s life.
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Ondansetron, a 5-HT3 receptor antagonist classically used for the treatment and prevention of
nausea and vomiting, may be beneficial as an off-label use in OCD. Our patient successfully
responded to ondansetron after failing first and second line treatment options. Considering
that results from studies are inconclusive but are showing promise with the use of ondansetron
in the treatment of OCD without significant adverse effects, the use of ondansetron should be
considered as an off-label attempt for treatment of obsessive thoughts in moderate to severe
OCD when first- and second-line treatment options fail.
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